# Harmony Biosciences Holdings share price today (Harmony Biosciences Holdings, Inc., HRMY)

> Harmony Biosciences Holdings, Inc.'s results are improving, while its P/E is near the low end of its own history over 4.6 years, higher than only 14% of past readings. HRMY · Healthcare · Biotechnology · data as of 5 November 2026. Page: https://www.sectoralpha.in/us/stocks/hrmy

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Slowing from a peak, from the last 12 quarters
- Price: $32.47 (+3.3% in a year)
- P/E: 10.7× (lower than 86% of the last 4.6 years)
- Revenue (Jun 2026): $261 M (+30.3% on a year ago)
- Profit (Jun 2026): $75.4 M (+89.6% on a year ago)
- Operating margin: 34.2% (+10.2 points on a year ago)
- ROE: 18%, FY25
- ROIC: 35.5%, against a 9.5% cost of capital: +26.0 points

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Harmony Biosciences Holdings share price today? Harmony Biosciences Holdings, Inc.'s share price was $32.47 at the close on 5 November 2026. It has been moving sideways for 1 week. That is 6.3% below its average price over the last 200 trading days. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 1 week running. In the last 52 weeks it traded between $27 and $42, and at that close it sat 38% of the way up from that low. Over the last 6.2 years the share price moved −10% while the S&P 500 moved +116%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 30 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Harmony Biosciences Holdings pay? Harmony Biosciences Holdings, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Harmony Biosciences Holdings on? Harmony Biosciences Holdings is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Harmony Biosciences Holdings profitable? Harmony Biosciences Holdings, Inc. earned $75.4 M of net profit in the Jun 2026 quarter, +89.6% on the same quarter a year earlier. Full-year FY25 profit was $159 M. Over 4 years profit has grown 46.3% a year on average. That is 28.9% of the quarter's revenue. The same quarter a year earlier earned $39.8 M. For the full year, FY25 profit was $159 M (+9.1% on the year before). Why profit moved: revenue changed +30.3% on a year earlier and the margin moved +10.2 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +4.2% and revenue +24.2%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Harmony Biosciences Holdings make, and is it growing? Harmony Biosciences Holdings, Inc. reported $261 M of revenue in the Jun 2026 quarter, +30.3% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 4 years it has grown 29.9% a year on average. The last full year, FY25, came in at $868 M. The last four reported quarters add to $960 M. FY25 revenue was $868 M, +21.5% on the year before. Recent pace: the last four quarters grew +24.2% on average, against 29.9% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +24.3%, against +21.0% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +0.2%, against +25.6% a year (rolling over). ## How much of every $100 of sales does Harmony Biosciences Holdings keep? Harmony Biosciences Holdings, Inc.'s operating margin was 34.2% in the Jun 2026 quarter, 10.2 percentage points higher than the same quarter a year ago. Across 5 years it has been between 24.0% and 33.0%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +10.2 percentage points on the year while gross margin changed −5.2 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Harmony Biosciences Holdings' profit turning into cash? Over the last 3 years, 182% of Harmony Biosciences Holdings, Inc.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $348 M of operating cash against $159 M of profit. After $310 K of spending on assets, $348 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Harmony Biosciences Holdings' cash go? Harmony Biosciences Holdings, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $1.8 M on assets over the last 3 years. Averaged over those years that is 0.1% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $1.8 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Harmony Biosciences Holdings' P/E ratio, and how does it compare with its own history? Harmony Biosciences Holdings, Inc.'s P/E is 10.7×, near the low end of its own history: it has been lower only 14% of the time. Its usual P/E (the middle reading) is 13.3×, over 4.6 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +8.0% while the price moved +3.3%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 3 years the price moved +7.8% a year; about +7.8% a year came from earnings growth and about +0.0 percentage points from the multiple (roughly no change). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Harmony Biosciences Holdings business getting better or worse? Harmony Biosciences Holdings, Inc.'s business is slowing from a peak. Profit and EPS growth have slowed sharply (profit growth from +51.4% at its peak to +0.2% now), while ROCE is still 22.3%. This is based on 12 quarters of 4 measures. Why it matters: slowing from a peak is where good stories often end quietly. ## How much does Harmony Biosciences Holdings earn on its capital? Harmony Biosciences Holdings, Inc. earned a ROE of 18% in FY25. Its return on capital used (ROIC) is 26.0 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 18.3% net margin and 0.68× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 18.3% net margin × 0.68× asset turnover × 1.46× leverage (assets divided by equity) ≈ 18.2% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 35.5% − 9.5% = +26.0 percentage points. The 9.5% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value. The 35.5% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 48.3%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Harmony Biosciences Holdings have too much debt? Harmony Biosciences Holdings, Inc. has total debt of $160 M against shareholder equity of $999 M as of Jun 2026, so its debt is 0.16× its equity, which is very little. Year by year, that ratio went from 1.05 in FY21 to 0.19 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Harmony Biosciences Holdings shareholding pattern? 10.4% of Harmony Biosciences Holdings, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 5.3 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Harmony Biosciences Holdings from balance-sheet trouble? For Harmony Biosciences Holdings, Inc., the Z-score is 4.90. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 4.90 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Harmony Biosciences Holdings rank in its industry? There is no score against its industry: Harmony Biosciences Holdings, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Harmony Biosciences Holdings compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Harmony Biosciences Holdings in size? Harmony Biosciences Holdings is the 78th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Zymeworks Inc., Fortrea Holdings Inc. and Mesoblast. Just below it: Vir Biotechnology, Inc., Sarepta Therapeutics, Inc. and Maravai LifeSciences Holdings, Inc. ### Biotechnology companies close in size

1. [Zymeworks Inc.](https://www.sectoralpha.in/us/stocks/zyme) $2 billion
2. [Fortrea Holdings Inc.](https://www.sectoralpha.in/us/stocks/ftre) $2 billion
3. [Mesoblast Limited](https://www.sectoralpha.in/us/stocks/meso) $2 billion
4. Harmony Biosciences Holdings, Inc. $1.9 billion
5. [Vir Biotechnology, Inc.](https://www.sectoralpha.in/us/stocks/vir) $1.9 billion
6. [Sarepta Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/srpt) $1.9 billion
7. [Maravai LifeSciences Holdings, Inc.](https://www.sectoralpha.in/us/stocks/mrvi) $1.8 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Maravai LifeSciences Holdings, Inc.](https://www.sectoralpha.in/us/stocks/mrvi) $2 billion · Biotechnology
2. [RLX Technology Inc.](https://www.sectoralpha.in/us/stocks/rlx) $2 billion · Tobacco
3. Harmony Biosciences Holdings, Inc. $2 billion
4. [Kennametal Inc.](https://www.sectoralpha.in/us/stocks/kmt) $2 billion · Tools & Accessories
5. [Stellar Bancorp, Inc.](https://www.sectoralpha.in/us/stocks/stel) $2 billion · Banks - Regional

## What else do people ask about Harmony Biosciences Holdings? ### What were Harmony Biosciences Holdings's latest quarterly results? Harmony Biosciences Holdings, Inc. reported revenue of $261 M and net profit of $75.4 M for the Jun 2026 quarter. Revenue rose 30.3% and profit rose 89.6% compared with a year earlier. Earnings per share were $1.28. The operating margin was 34.2%, 10.2 percentage points higher than a year earlier (as of 5 November 2026). ### What is Harmony Biosciences Holdings's market cap? Harmony Biosciences Holdings, Inc.'s market capitalisation is $1.9 B at a stock price of $32.47. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 5 November 2026). ### How is Harmony Biosciences Holdings performing? Harmony Biosciences Holdings, Inc.'s share price has been moving sideways for 1 weeks. In its latest quarter, revenue rose 30.3% and profit rose 89.6% compared with a year earlier. Over the past 13 weeks it has done worse than the S&P 500, for 1 week running (as of 5 November 2026). ### Will Harmony Biosciences Holdings's stock price go up? This page does not forecast Harmony Biosciences Holdings, Inc.'s stock price. What it shows instead: the stock price is $32.47, and it has been moving sideways for 1 weeks. Its P/E of 10.7× is higher than 14% of its own last 5 years (as of 5 November 2026). ### Does Harmony Biosciences Holdings have too much debt? No, Harmony Biosciences Holdings, Inc. has little debt: its debt is 0.14× its equity. A year-by-year history of its borrowings is not in our data, so this uses the latest reading. So the returns on this page come from the business, not borrowed money (as of 5 November 2026). ### Where is Harmony Biosciences Holdings in its business cycle? Harmony Biosciences Holdings, Inc.'s FY25 operating margin was 24.0%, against a 5-year range of 24.0% to 33.0%: the low end of its own range, which is often where recoveries start. The latest quarter was 34.2%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 5 November 2026). ### What could break the Harmony Biosciences Holdings story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 5 November 2026). ### Is Harmony Biosciences Holdings a stock worth studying right now? What the numbers show: Harmony Biosciences Holdings, Inc.'s results are improving, while its P/E is near the low end of its own history over 4.6 years, higher than only 14% of past readings. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 5 November 2026). This is research, not advice. We’re not SEBI-registered.